Why the study?
Accurate prediction of mortality risk in patients with HFpEF remains an unmet clinical need.
Does a 10-metabolite prognostic model improve the prediction of 4-year all-cause mortality compared to a clinical risk score in hospitalized Chinese Han patients with HFpEF?
Population
500 hospitalized Chinese Han patients with HFpEF from a national multicenter prospective cohort
Comparison
10-metabolite prognostic model vs clinical risk score
Design
Prospective cohort study with metabolomic and transcriptomic analyses
Follow-up
4 years
Key result
A 10-metabolite model predicted 4-year all-cause mortality in HFpEF, with the highest tertile having a 23-fold increased risk compared to the lowest tertile (HR 22.95; 95% CI 11.07-57.54).
Authors
Loading...
May refine mortality prediction beyond clinical scores in HFpEF; hypothesis-generating and requires prospective validation before practice change.
Cohort (n=500)
Yes
Does a 10-metabolite prognostic model improve the prediction of 4-year all-cause mortality compared to a clinical risk score in hospitalized Chinese Han patients with HFpEF?
Hazard Ratio: 22.95 (95% CI 11.07–57.54)
A novel 10-metabolite prognostic model significantly improves the prediction of 4-year all-cause mortality in hospitalized Chinese Han patients with HFpEF compared to standard clinical risk scores.
Li et al. (2026) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=500). Highest tertile of 10-metabolite score vs. Lowest tertile of 10-metabolite score was evaluated on 4-year all-cause mortality (HR 22.95, 95% CI 11.07-57.54). A 10-metabolite model predicted 4-year all-cause mortality in HFpEF, with the highest tertile having a 23-fold increased risk compared to the lowest tertile (HR 22.95; 95% CI 11.07-57.54).